We are proud to share another edition of Updates from the Lab! We have been hard at work this year, and are pleased to share our recent breaking news, programming developments, and grant updates.
“Jeffrey’s Insights” Genetic Sequencing
Earlier this year we announced our new partnership with Veritas, a letsgetchecked company focused on genome and exome sequencing and clinical interpretation. Through this new collaboration, our “Jeffrey’s Insights” genetic sequencing program will continue to be available at no cost to all Jeffrey Modell Centers Network (JMCN) physicians with patients who are suspected of an underlying Primary Immunodeficiency (PI) or other inborn errors of immunity. Read the full press release here.
Breaking News
Pharming Group N.V. announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib), to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. Read the full press release.
Translational Research Program
Cycle 11 of the Translational Research program is underway. Letters of intent were submitted on March 16, and invited applicants will submit their materials by July 6, 2023. We are looking forward to reviewing applications in the coming months.
Specific Defect Research Program
Awards for the Specific Defect Research Program are granted on a rolling basis throughout the year. Each award amounts up to $50,000 over a two-year project period, with a maximum of $25,000 per year. Learn more or apply here.
c.h.i.l.d.r.e.n! Research Program
The c.h.i.l.d.r.e.n! grants are awarded on a rolling basis throughout the year. Each award amounts up to $25,000 per year, for up to two years, following peer-review and approval. The focus of this grant program is to investigate immunological disorders, infectious disease, initiatives to decrease infant mortality and ultimately improve the quality of life of children affected by Primary Immunodeficiency globally.